Regencell bioscience announces additional earth efficacy trial results corroborating effectiveness of its investigational liquid-formula rgc-cov19tm in eliminating mild to moderate covid-19 symptoms within the 6-day treatment period

Hong kong--(business wire)---- $rgc #adhd--regencell bioscience holdings limited (nasdaq: rgc): results of earth efficacy trial   earth efficacy trials period of trial 30 january 2022 – 31 march 2022 (earth-b trial) 1 october 2021 – 31 january 2022 (earth-a trial) 1 october 2021 – 31 march 2022 (earth-a and earth-b trials, combined) number of patients 51 37 88 complete symptoms elimination in 6 days (% of patients) 94.1 97.3 95.5 elimination of one or more symptoms after 1 full dose of rgc-cov19tm (% of patie
RGC Ratings Summary
RGC Quant Ranking